Diverging Effects of Human Recombinant Anti-Hepatitis C Virus (HCV) Antibody Fragments Derived from a Single Patient on the Infectivity of a Vesicular Stomatitis Virus/HCV Pseudotype
about
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infectionsJC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes?Replication-Competent Recombinant Vesicular Stomatitis Virus Encoding Hepatitis C Virus Envelope ProteinsIdentification of a Broadly Cross-Reacting and Neutralizing Human Monoclonal Antibody Directed against the Hepatitis C Virus E2 ProteinHepatitis C Virus (HCV) Infection May Elicit Neutralizing Antibodies Targeting Epitopes Conserved in All Viral GenotypesPhage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogensMechanisms of hepatitis C virus infection.Neutralization interfering antibodies: a "novel" example of humoral immune dysfunction facilitating viral escape?Molecular signatures of hepatitis C virus (HCV)-induced type II mixed cryoglobulinemia (MCII).Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.Multiantibody strategies for HIV.Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies.Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab.
P2860
Q24289014-70C7F210-AFE4-4299-AFFF-34854B29D6B7Q26852060-953F0E65-4474-47CC-AD70-7A5564ACA6BCQ27481021-834FA477-4D19-48A8-A834-D882F5695252Q27485318-D1DB9A2A-3B22-455C-883E-446BF72D2E8CQ27490450-DE9F4DA7-3759-4B8A-95E2-99B0D57AA6E5Q34401573-4F01ED7D-A569-4A8D-8C5E-60E8D6C20E14Q35669529-571B6A9E-3A7F-4AE7-A23E-465D011380A7Q36404194-E364B1D0-A1D2-401A-AF22-91388D6A570BQ36432725-6020908D-6713-40EF-A977-7613E095AC27Q36682313-B7928C25-69DE-40E9-8AD6-7C0035AFCE4AQ38120526-182C4129-B9C1-46F5-A9B4-D94B8DD86791Q38128299-BA167D8E-3A12-4491-A539-45F95AC0CC33Q40761630-35DB5CC6-4A38-4C02-950E-008222A5977E
P2860
Diverging Effects of Human Recombinant Anti-Hepatitis C Virus (HCV) Antibody Fragments Derived from a Single Patient on the Infectivity of a Vesicular Stomatitis Virus/HCV Pseudotype
description
2002 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2002-11)
@fr
articolo scientifico (pubblicato il 2002-11)
@it
artigo científico (publicado na 2002-11)
@pt
artículu científicu espublizáu en 2002
@ast
im November 2002 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: November 2002)
@en
vedecký článok (publikovaný 2002-11)
@sk
vetenskaplig artikel (publicerad på 2002-11)
@sv
name
Diverging Effects of Human Rec ...... tomatitis Virus/HCV Pseudotype
@ast
Diverging Effects of Human Rec ...... tomatitis Virus/HCV Pseudotype
@en
Diverging Effects of Human Rec ...... tomatitis Virus/HCV Pseudotype
@nl
type
label
Diverging Effects of Human Rec ...... tomatitis Virus/HCV Pseudotype
@ast
Diverging Effects of Human Rec ...... tomatitis Virus/HCV Pseudotype
@en
Diverging Effects of Human Rec ...... tomatitis Virus/HCV Pseudotype
@nl
prefLabel
Diverging Effects of Human Rec ...... tomatitis Virus/HCV Pseudotype
@ast
Diverging Effects of Human Rec ...... tomatitis Virus/HCV Pseudotype
@en
Diverging Effects of Human Rec ...... tomatitis Virus/HCV Pseudotype
@nl
P2093
P2860
P50
P921
P3181
P1433
P1476
Diverging effects of human rec ...... tomatitis virus/HCV pseudotype
@en
P2093
Hideki Tani
Roberto Burioni
Tatsuo Miyamura
Yoshiharu Matsuura
P2860
P304
11775-11779
P3181
P356
10.1128/JVI.76.22.11775-11779.2002
P577
2002-11-01T00:00:00Z